Until recently, patients with relapsed Hodgkin's lymphoma after brentuximab vedotin (Bv)
treatments had poor treatment outcomes. Checkpoint inhibitors such as nivolumab and …

Hodgkin lymphoma is a highly curable malignancy involving lymph nodes and the lymphatic
system. Even at late stage disease, about 70% of patients will be cured with standard first …

Hodgkin lymphoma treatment continues to evolve as new means of assessing response to
treatment, new appreciation of important risk factors, and more effective therapeutic agents …

Hodgkin Lymphoma (HL) is a unique disease entity both in its pathology and the young
patient population that it primarily affects. Although cure rates are high, survivorship can be …

Opinion statement Patients with Hodgkin lymphoma (HL) can achieve excellent response
and survival rates following frontline combination chemo-and radiation therapy. However …

Simple Summary The introduction of immunotherapy into the treatment options for Hodgkin's
lymphoma has improved survival in patients with recurrence of their cancer. These agents …

Background Patients with classical Hodgkin's lymphoma (cHL) have a good prognosis even
in advanced stages. However, combined chemo-and radiotherapy, as the standard of care …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

Background Recognising that the immune suppressive microenvironment promotes tumour
growth in Hodgkin lymphoma, we hypothesised that activating immunity might augment the …

Immune checkpoint inhibitors (ICIs) have demonstrated remarkable response rates in
relapsed or refractory Hodgkin lymphoma (HL). Still, most patients eventually progress …